z-logo
open-access-imgOpen Access
Lack of association between Cyclin D1 gene G870A polymorphism and esophageal cancer: evidence from a meta-analysis
Author(s) -
Wei Cai,
Z.T. Wang,
Jian Zhong,
Y. Zhang
Publication year - 2013
Publication title -
genetics and molecular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.356
H-Index - 48
ISSN - 1676-5680
DOI - 10.4238/2013.april.26.1
Subject(s) - esophageal cancer , odds ratio , meta analysis , genotype , confidence interval , genotyping , publication bias , medicine , allele , oncology , subgroup analysis , funnel plot , cyclin d1 , genetics , gastroenterology , biology , gene , cancer , cell cycle
The association between the Cyclin D1 gene (CCND1) G870A polymorphism and esophageal cancer has been widely evaluated, with conflicting results. As meta-analysis is a reliable approach to resolving discrepancies, we aimed to evaluate this association. Data were available from 9 study populations incorporating 1898 cases and 3046 controls. Overall, the allelic/genotypic association between the G870A polymorphism and esophageal cancer was nonsignificant [for allele: odds ratio (OR) = 1.14, 95% confidence interval (95%CI) = 0.94-1.38, P = 0.184; for genotype homozygous comparison: OR = 1.36, 95%CI = 0.90-2.06, P = 0.140; for dominant model: OR = 1.24, 95%CI = 0.88-1.75, P = 0.222; for recessive model: OR = 1.13, 95%CI = 0.90-1.43, P = 0.292]. Moreover, subgroup analyses according to study designs, geographic areas, types of esophageal cancer, genotyping methods, and ethnicities failed to demonstrate a significant association between this polymorphism and esophageal cancer. In addition, there was significant publication bias as reflected by funnel plots and the Egger test (P = 0.042). Taken together, our results suggest that the CCND1 G870A polymorphism might not be a potential candidate for predicting esophageal cancer risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here